Objective:To investigate the efficacy and safety of edaravone-defibrase combination in treatment of acute cerebral infarction. Methods: The patients with acute cerebral infarction within 12 hours of stroke onset were divided randomly into two groups:group A(46 cases)and group B(47 cases). Group A were treated with edaravone(30mg, twice a day,for 14 days)and de-fibrase(initial 15 U, subsequent 5U on the 3th,5th,7th,9th day) (and group B were treated only with defibrase. The neurological deficit scores of European stroke scale(ESS) .activities of daily living( ADD,acute physiology and chronic health evalution II (APACHE) II scores and C-reactive protein(CRP)level were evaluated before and after treatment; the efficacy was evaluated after the treatment. Results: After the 14th day treatment,there were significant difference of all the four variablesCESS, ADL, APACHE II and CRP)in two groups than before treatment,all the four variables of group A were better than group B;the efficient rate of group A(67.4%)was higher than group B(40. 4%) (P<0. 05) (There was no significant difference for the mortality at 3 months between two groups(P>0. 05) (There were several patients with extracranial hemorrhage and there was no significant difference between two groups(P>0. 05), there was no intracranial hemorrhage in all patientst there was no severe adverse reaction in two groups. Conclusions: Edaravone-defibrase combination is effective and safe in treatment of acute cerebral infarction.%目的:探讨依达拉奉联用降纤酶治疗急性脑梗死的临床疗效及安全性.方法:发病12h内的急性脑梗死患者93例,随机分为A组46例和B组47例.A组患者用依达拉奉注射液(30 mg加入0.9％氯化钠液100 mL静脉滴注,2次/d,共14 d)和降纤酶(首剂量为15U,以后隔日给予5U,共4次,均加入0.9％氯化钠液250 mL,2～3 h内静脉滴注)；B组患者仅用降纤酶治疗.治疗前后对患者进行欧洲脑卒中量表(ESS)神经功能缺损程度评分、日常生活能力(ADL)评分、急性生理功能和慢性健康状况评分(APACHE)Ⅱ评分及C反应蛋白(CRP)测定,随访时间3个月.结果:治疗后14 d,2组患者的ESS、ADL、APACHE Ⅱ和CRP较治疗前有显著改善,A组的各项指标优于B组；A组有效率(67.4％)显著高于B组(40.4％)(P＜0.05)；3个月病死率2组无显著差异(P＞0.05);2组患者均无颅内出血发生,少数患者发生颅外出血,2组差异无统计学意义,所有病例无严重不良反应发生.结论:依达拉奉联用降纤酶治疗急性脑梗死安全、有效.
展开▼
